title: [Probiotics as therapeutic agents in irritable bowel syndrome].
abstract: Probiotics are defined as living micro-organisms which, when administered in large amounts, confer a health benefit on the host. The use of probiotics in the therapy of infectious bowel diseases as well as maintaining remission of ulcerative colitis and in pouchitis is evidence-based. Also, in several studies proof could be supplied that specific probiotics relieve the symptoms and the course of irritable bowel syndrome. Some trials showed a significant improvement of irritable bowel syndrome-related constipation via Lactobacillus casei Shirota and E. coli Nissle 1917. Lactobacillus plantarum has been proven effective in reducing pain and abdominal bloating. However, in most of the studies rather small numbers of patients were examined. Furthermore, these studies do not always closely follow scientific standards (randomised, double-blind, placebo-controlled). Therefore, confirmatory studies are necessary to examine the effect of probiotics in irritable bowel syndrome.
authors.affiliation: II. Medizinische Universitätsklinik (Gastroenterologie, Hepatologie, Infektionskrankheiten), Universitätsklinikum Mannheim. h.krammer@med.ma.uni-heidelberg.de
authors.forename: H-J
authors.initials: HJ
authors.lastname: Krammer
authors.forename: F
authors.initials: F
authors.lastname: Schlieger
authors.forename: H
authors.initials: H
authors.lastname: Harder
authors.forename: A
authors.initials: A
authors.lastname: Franke
authors.forename: M V
authors.initials: MV
authors.lastname: Singer
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000628:therapy*; D007780:Lacticaseibacillus casei; D048191:Lactiplantibacillus plantarum; D019936:Probiotics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome